Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)
- Registration Number
- NCT03444870
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This randomized, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of gantenerumab versus placebo in participants with early (prodromal to mild) AD. All participants must show evidence of beta-amyloid pathology. Eligible participants will be randomized 1:1 to receive either subcutaneous (SC) injection of ganteneruma...
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 1053
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Gantenerumab Gantenerumab Gantenerumab will be administered as SC injections with gradual uptitration. Placebo Placebo Placebo will be administered as SC injections with gradual uptitration.
- Primary Outcome Measures
Name Time Method DBT Period: Change From Baseline to Week 116 in Global Outcome, as Measured by CDR-SB Baseline, Week 116 CDR was derived through semi-structured interview with the participant and an appropriate informant, and it rated impairment across six domains: memory, orientation, judgment, and problem solving, community affairs, home and hobbies, and personal care on a 5-point scale for which 0=no impairment, 0.5=questionable impairment, and 1, 2, and 3=mild, moderate, a...
China Extension: DBT Period: Change From Baseline to Week 116 in Global Outcome, as Measured by CDR-SB Baseline, Week 116 CDR was derived through semi-structured interview with the participant and an appropriate informant, and it rated impairment across six domains: memory, orientation, judgment, and problem solving, community affairs, home and hobbies, and personal care on a 5-point scale for which 0=no impairment, 0.5=questionable impairment, and 1, 2, and 3=mild, moderate, a...
- Secondary Outcome Measures
Name Time Method DBT Period: Change From Baseline to Week 116 in Verbal Fluency Task (VFT) Score Baseline, Week 116 VFT is a rater administered PerfO that measures speed and flexibility of verbal thought with a total score that ranges from 0-99 (lower scores indicating lower performance). A positive change from baseline indicates improvement.
DBT Period: Change From Baseline to Week 116 in the Coding (Digit Symbol Substitution Test [DSST]) Subtest Baseline, Week 116 Coding, also called DSST is a rater administered PerfO that measures speed of processing and associative memory with a total score that ranges from 0-135 (lower scores indicating lower performance). The DSST was adapted from the Wechsler Adult Intelligence Scale. The 120-second version of the test was used in this study. Positive change from baseline indicat...
DBT Period: Change From Baseline to Week 116 in Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living (ADCS-iADL) Instrumental Score Baseline, Week 116 The ADCS-iADL measures activities such as using the telephone, shopping and preparing a meal. The ADCS-iADL consists of 16 questions with a score range of 0 to 56 where a higher score represents better function. Positive change from baseline indicates improvement.
DBT Period: Number of Participants With at Least One Adverse Event (AE) From Day 1 up to 14 weeks after the last dose of blinded study drug (up to 131 weeks) An AE is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution.
DBT Period: Change From Baseline to Week 116 in Alzheimer Disease Assessment Scale-Cognition Subscale 13 (ADAS-Cog13) Score Baseline, Week 116 The ADAS-Cog13 total score includes all of the items in the ADAS-Cog11 in addition to delayed word recall and the number cancellation. For the ADAS-cog 13 the range is 0-85 (score range for Delayed Word Recall \[DWR\] score is 0-10 and for Number Cancellation \[NC\] is 0-5, thus the score is ADAS-cog 11\[0-70\] plus the scores for DWR and NC). A higher score...
DBT Period: Change From Baseline to Week 116 in Alzheimer's Disease Cooperative Study- Activities of Daily Living (ADCS-ADL) Total Score Baseline, Week 116 ADCS-ADL is a 23-item rater-administered, observer-reported outcome (ObsRO) that captures a participant's ability to perform basic activities of daily living (e.g., eating and toileting) and more complex ADL or instrumental activities of daily living (iADL, e.g., using the telephone, managing finances, preparing a meal). Total score ranges from 0-78, with hi...
DBT Period: Change From Baseline to Week 116 in Functional Activities Questionnaire (FAQ) Score Baseline, Week 116 FAQ is a rater-administered ObsRO (informant-based measure) that measures a participant's functional ability to perform complex higher-order activities. The observer provides performance ratings of the target person on ten complex higher-order activities. Total score that ranges from 0-30, with higher scores reflecting greater functional impairment. A negati...
DBT Period: Change From Baseline to Week 116 in Mini-Mental State Examination (MMSE) Total Score Baseline, Week 116 MMSE is a rater-administered performance-based outcome (PerfO) that includes a set of standardized questions used to evaluate possible cognitive impairment and help stage the severity level of this impairment. The questions target six areas: orientation, registration, attention, short-term recall, language, and constructional praxis/visuospatial abilities. T...
DBT Period: Change From Baseline to Week 116 in Alzheimer Disease Assessment Scale-Cognition Subscale 11 (ADAS-Cog11) Score Baseline, Week 116 The ADAS-Cog11 was designed to measure cognitive symptom change in participants with Alzheimer's Disease (AD) and consisted of 11 tasks. The standard 11 items (and corresponding score range) were: word recall (0-10), commands (0-5), constructional praxis (0-5), naming objects and fingers (0-5), ideational praxis (0-5), orientation (0-8), word recognition (0-...
DBT Period: Number of Participants With Post-baseline Suicidal Ideation or Suicidal Behavior as Measured Using Columbia-Suicide Severity Rating Scale (C-SSRS) From Day 1 up to 14 weeks after the last dose of blinded study drug (up to 131 weeks) C-SSRS=assessment tool used to assess lifetime suicidality of a participant (at baseline) as well as any new instances of suicidality (C-SSRS since last visit). Structured interview prompts recollection of suicidal ideation, including intensity of ideation, behavior, \& attempts with actual/potential lethality. Categories have binary responses (yes/no) \& in...
DBT Period: Number of Participants With at Least One Amyloid-Related Imaging Abnormalities-Haemosiderin Deposition (ARIA-H) MRI Finding From Day 1 up to 14 weeks after the last dose of blinded study drug (up to 131 weeks) ARIA are an identified risk with anti-amyloid antibodies, including gantenerumab. These changes can be identified on brain MRI. ARIA-H (H for hemosiderosis) are small foci of signal loss observed on MRI sequences sensitive for paramagnetic tissue properties and comprise cerebral microbleeds (small foci of bleeding in the brain parenchyma) and leptomeningeal ...
DBT Period: Number of Participants With at Least One Amyloid-Related Imaging Abnormalities-Edema (ARIA-E) Magnetic Resonance Imaging (MRI) Finding From Day 1 up to 14 weeks after the last dose of blinded study drug (up to 131 weeks) ARIA are an identified risk with anti-amyloid antibodies, including gantenerumab. These changes can be identified on brain MRI. In ARIA-E, (E for oedema or effusion), oedema can be seen in different areas of the brain on MRI, representing fluid leakage into the brain parenchyma or sulcal spaces.
DBT Period: Number of Participants With Injection-Site Reactions From Day 1 up to 14 weeks after the last dose of blinded study drug (up to 131 weeks) An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product or other protocol-imposed intervention, regardless of attribution. Local injection reactions (or injection site reactions) are defined as AEs related to the injection site that occur during or within 24 hours after study drug adm...
DBT Period: Number of Participants With Anti-Drug Antibodies (ADA) to Gantenerumab From Day 1 up to 14 weeks after the last dose of blinded study drug (up to 131 weeks) The number of participants with positive results for ADA against gantenerumab at any of the post-baseline assessment time-points were reported. Participant with an ADA assay result from at least one post-baseline sample was defined as a post-baseline evaluable participant. Treatment Emergent ADA = A participant with a negative or missing baseline ADA result(...
DBT Period: Change From Baseline to Week 116 in Brain Amyloid Load as Measured by Amyloid Positron Emission Tomography (PET) Scan in a Subset of Participants Baseline, Week 116 Brain amyloid load over time was assessed using \[18F\] florbetaben or \[18F\] flutemetamol tracers. These are PET radioligand selective to amyloid. Amyloid PET burden was measured in a composite region of interest (ROI) by using standardized uptake value ratio (SUVR) mapped to the centiloid scale. The weighted composite target region are composed of (both l...
DBT Period: Change From Baseline to Week 116 in Brain Tau Load, as Measured by Tau PET Scan in a Subset of Participants Baseline, Week 116 Change in tau load= how much neurofibrillary tau pathology is present in brain assessed by PET Scan. \[18F\] GTP1 was the tau PET radioligand. Tau load was measured using SUVR in 4 composite target ROIs: Temporal composite target region (left \& right)=anterior \& posterior superior temporal gyrus, posterior temporal lobe, fusiform gyrus, \& middle \& inferi...
DBT Period: Percent Change From Baseline to Week 116 in Cerebrospinal Fluid (CSF) Marker of Disease in a Subset of Participants - Total Tau (tTau) Baseline, Week 116 CSF biomarker tTau has been considered as a general marker of neurodegeneration. An elevation in levels of tau, as well as specific pTau species, is thought to be a marker for progressive cellular degeneration in AD.
DBT Period: Percent Change From Baseline to Week 116 in CSF Marker of Disease in a Subset of Participants - Phosphorylated Tau (pTau-181) Baseline, Week 116 CSF phospho-tau is an indicator of neuronal injury and neurodegeneration. CSF biomarker tTau has been considered as a general marker of neurodegeneration. An elevation in levels of pTau species, is thought to be a marker for progressive cellular degeneration in AD.
DBT Period: Percent Change From Baseline to Week 116 in CSF Marker of Disease in a Subset of Participants - Neurofilament Light Chain (NFL) Baseline, Week 116 NFL is a neuronal cytoplasmic protein highly expressed in large, myelinated axons. Its levels increase in CSF and blood proportionally to the degree of axonal damage in a variety of neurological disorders, including AD.
DBT Period: Percent Change From Baseline to Week 116 in CSF Marker of Disease in a Subset of Participants - Neurogranin Baseline, Week 116 China - DBT Period: Change From Baseline to Week 116 in ADAS-Cog13 Score Baseline, Week 116 The ADAS-Cog13 total score includes all of the items in the ADAS-Cog11 in addition to delayed word recall and the number cancellation. For the ADAS-cog 13 the range is 0-85 (score range for Delayed Word Recall \[DWR\] score is 0-10 and for Number Cancellation \[NC\] is 0-5, thus the score is ADAS-cog 11\[0-70\] plus the scores for DWR and NC). A higher score...
China - DBT Period: Change From Baseline to Week 116 in ADCS-ADL Total Score Baseline, Week 116 ADCS-ADL is a 23-item rater-administered, ObsRO that captures a participant's ability to perform basic activities of daily living (e.g., eating and toileting) and more complex ADL or instrumental activities of daily living (iADL, e.g., using the telephone, managing finances, preparing a meal). Total score ranges from 0-78, with higher scores reflecting bette...
China - DBT Period: Change From Baseline to Week 116 in FAQ Score Baseline, Week 116 FAQ is a rater-administered ObsRO (informant-based measure) that measures a participant's functional ability to perform complex higher-order activities. The observer provides performance ratings of the target person on ten complex higher-order activities. Total score that ranges from 0-30, with higher scores reflecting greater functional impairment. A negati...
China - DBT Period: DBT Period: Change From Baseline to Week 116 in MMSE Total Score Baseline, Week 116 MMSE is a rater-administered PerfO that includes a set of standardized questions used to evaluate possible cognitive impairment and help stage the severity level of this impairment. The questions target six areas: orientation, registration, attention, short-term recall, language, and constructional praxis/visuospatial abilities. Total score ranges from 0-30,...
China - DBT Period: Change From Baseline to Week 116 in ADAS-Cog11 Score Baseline, Week 116 The ADAS-Cog11 was designed to measure cognitive symptom change in participants with AD and consisted of 11 tasks. The standard 11 items (and corresponding score range) were: word recall (0-10), commands (0-5), constructional praxis (0-5), naming objects and fingers (0-5), ideational praxis (0-5), orientation (0-8), word recognition (0-12), spoken language a...
China - DBT Period: Change From Baseline to Week 116 in VFT Score Baseline, Week 116 VFT is a rater administered PerfO that measures speed and flexibility of verbal thought with a total score that ranges from 0-99 (lower scores indicating lower performance). A positive change from baseline indicates improvement.
China - DBT Period: Change From Baseline to Week 116 in the Coding (DSST) Subtest Baseline, Week 116 Coding, also called DSST is a rater administered PerfO that measures speed of processing and associative memory with a total score that ranges from 0-135 (lower scores indicating lower performance). The DSST was adapted from the Wechsler Adult Intelligence Scale. The 120-second version of the test was used in this study. Positive change from baseline indicat...
China - DBT Period: Number of Participants With at Least One AE From Day 1 up to 14 weeks after the last dose of blinded study drug (up to 124 weeks) An AE is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. Total number of participants with at least one event (AEs) have been reported here.
China - DBT Period: Number of Participants With Post-baseline Suicidal Ideation or Suicidal Behavior as Measured Using C-SSRS From Day 1 up to 14 weeks after the last dose of blinded study drug (up to 124 weeks) C-SSRS=assessment tool used to assess lifetime suicidality of a participant (at baseline) as well as any new instances of suicidality (C-SSRS since last visit). Structured interview prompts recollection of suicidal ideation, including intensity of ideation, behavior, \& attempts with actual/potential lethality. Categories have binary responses (yes/no) \& in...
China - DBT Period: Number of Participants With at Least One ARIA-E MRI Finding From Day 1 up to 14 weeks after the last dose of blinded study drug (up to 124 weeks) ARIA are an identified risk with anti-amyloid antibodies, including gantenerumab. These changes can be identified on brain MRI. In ARIA-E, (E for oedema or effusion), oedema can be seen in different areas of the brain on MRI, representing fluid leakage into the brain parenchyma or sulcal spaces.
China - DBT Period: Number of Participants With at Least One ARIA-H MRI Finding From Day 1 up to 14 weeks after the last dose of blinded study drug (up to 124 weeks) ARIA are an identified risk with anti-amyloid antibodies, including gantenerumab. These changes can be identified on brain MRI. ARIA-H (H for hemosiderosis) are small foci of signal loss observed on MRI sequences sensitive for paramagnetic tissue properties and comprise cerebral microbleeds (small foci of bleeding in the brain parenchyma) and leptomeningeal ...
China - DBT Period: Number of Participants With Injection-Site Reactions From Day 1 up to 14 weeks after the last dose of blinded study drug (up to 124 weeks) An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product or other protocol-imposed intervention, regardless of attribution. Local injection reactions (or injection site reactions) are defined as AEs related to the injection site that occur during or within 24 hours after study drug adm...
OLE Period: Number of Participants With at Least One AEs From day of first dose in OLE period up to 14 weeks after the last OLE dose (up to 68 weeks) An AE is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution.
OLE Period: Number of Participants With Post-baseline Suicidal Ideation or Suicidal Behavior as Measured Using C-SSRS From day of first dose in OLE period up to 14 weeks after the last OLE dose (up to 68 weeks) C-SSRS=assessment tool used to assess lifetime suicidality of a participant (at baseline) as well as any new instances of suicidality (C-SSRS since last visit). Structured interview prompts recollection of suicidal ideation, including intensity of ideation, behavior, \& attempts with actual/potential lethality. Categories have binary responses (yes/no) \& in...
OLE Period: Number of Participants With at Least One ARIA-H MRI Finding From day of first dose in OLE period up to 14 weeks after the last OLE dose (up to 68 weeks) ARIA are an identified risk with anti-amyloid antibodies, including gantenerumab. These changes can be identified on brain MRI. ARIA-H (H for hemosiderosis) are small foci of signal loss observed on MRI sequences sensitive for paramagnetic tissue properties and comprise cerebral microbleeds (small foci of bleeding in the brain parenchyma) and leptomeningeal ...
OLE Period: Number of Participants With at Least One ARIA-E MRI Finding From day of first dose in OLE period up to 14 weeks after the last OLE dose (up to 68 weeks) ARIA are an identified risk with anti-amyloid antibodies, including gantenerumab. These changes can be identified on brain MRI. In ARIA-E, (E for oedema or effusion), oedema can be seen in different areas of the brain on MRI, representing fluid leakage into the brain parenchyma or sulcal spaces.
Trial Locations
- Locations (172)
Bradenton Research Center
🇺🇸Bradenton, Florida, United States
Neurology Consultants of Dallas; Research Department
🇺🇸Dallas, Texas, United States
Sunnybrook Health Sciences Centre
🇨🇦Toronto, Ontario, Canada
Baycrest Health Sciences
🇨🇦Toronto, Ontario, Canada
Ospedale San Giovanni Calibita Fatebenefratell;Neurologia
🇮🇹Roma, Lazio, Italy
Australian Alzheimer's Research Foundation
🇦🇺Nedlands, Western Australia, Australia
IRCCS Neuromed; Neurologia I-Centro studio e cura delle demenze e UVA
🇮🇹Pozzilli, Molise, Italy
Guangdong Provincial People's Hospital; Breast
🇨🇳Guangzhou City, China
Sun Yat-sen Memorial Hospital; Neurology
🇨🇳Guangzhou, China
The First Affiliated Hospital of Anhui Medical University
🇨🇳Hefei, China
The Second Affiliated Hospital to Nanchang University
🇨🇳Nanchang, China
Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School
🇨🇳Nanjing City, China
Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University)
🇨🇳Nanjing City, China
Ruijin Hospital Shanghai Jiaotong University School of Medicine
🇨🇳Shanghai City, China
Huashan Hospital Affiliated to Fudan University
🇨🇳Shanghai City, China
Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
🇨🇳Shanghai, China
Northern Jangsu People's Hospital
🇨🇳Yangzhou City, China
Shanghai First People's Hospital
🇨🇳Shanghai, China
Center for Neurosciences
🇺🇸Tucson, Arizona, United States
Global Clinical Trials; Irvine, CA
🇺🇸Irvine, California, United States
California Neuroscience Research Medical Group, Inc
🇺🇸Sherman Oaks, California, United States
Instituto de Neurologia de Curitiba
🇧🇷Curitiba, PR, Brazil
Center for Advanced Research & Education
🇺🇸Gainesville, Georgia, United States
The Clinical Trial Center, LLC
🇺🇸Jenkintown, Pennsylvania, United States
Beijing Tian Tan Hospital,Capital Medical University
🇨🇳Beijing City, China
Neurological Associates of Long Island, PC
🇺🇸Lake Success, New York, United States
Universitätsklinikum Ulm; Klinik für Neurologie
🇩🇪Ulm, Germany
PANAKEIA - Arzneimittelforschung Leipzig GmbH
🇩🇪Leipzig, Germany
Universitätsmedizin derJohannes Gutenberg-Universität Mainz;Klinik für Psychiatrie und Psychotherapi
🇩🇪Mainz, Germany
Central Clinical Hospital #2 N.A. Semashko OAO RJHD
🇷🇺Moskva, Moskovskaja Oblast, Russian Federation
Medical Corporation Hakuyokai Kashiwado Hospital
🇯🇵Chiba, Japan
Fondazione Santa Lucia IRCCS; Neurologia e Riabilitazione Neurologica
🇮🇹Roma, Lazio, Italy
Southern Tohoku Medical Clinic
🇯🇵Fukushima, Japan
Hospital Vall d'Hebron; Servicio de Neurología
🇪🇸Barcelona, Spain
Hospital Ruber Internacional; Servicio de Neurología
🇪🇸Madrid, Spain
Chang Gung Memorial Foundation - Linkou - Neurology
🇨🇳Taoyuan, Taiwan
University of Virginia
🇺🇸Charlottesville, Virginia, United States
Research Center for Clinical Studies, Inc.
🇺🇸Norwalk, Connecticut, United States
University of Mississippi Medical Center
🇺🇸Jackson, Mississippi, United States
China Medical University Hospital; Neurology
🇨🇳North Dist., Taiwan
State autonomous institution of healthcare Inter-regional clinical and diagnostic center
🇷🇺Kazan, Tatarstan, Russian Federation
Syrentis Clinical Research
🇺🇸Santa Ana, California, United States
JEM Research LLC
🇺🇸Atlantis, Florida, United States
Columbus Memory Center
🇺🇸Columbus, Georgia, United States
Brain Matters Research, Inc.
🇺🇸Delray Beach, Florida, United States
Alzheimer?s Research and Treatment Center
🇺🇸Wellington, Florida, United States
Southern Illinois University, School of Medicine
🇺🇸Springfield, Illinois, United States
Fort Wayne Neurological Center
🇺🇸Fort Wayne, Indiana, United States
Via Christi Research
🇺🇸Wichita, Kansas, United States
Precise Research Centers
🇺🇸Flowood, Mississippi, United States
Advanced Memory Research Institute of NJ
🇺🇸Toms River, New Jersey, United States
Ohio State University; College of Medicine
🇺🇸Columbus, Ohio, United States
Columbia University Medical Center
🇺🇸New York, New York, United States
Abington Neurological Associates
🇺🇸Abington, Pennsylvania, United States
Drexel University; College of Medicine
🇺🇸Philadelphia, Pennsylvania, United States
Coastal Neurology
🇺🇸Port Royal, South Carolina, United States
Sentara Neurology Specialists
🇺🇸Norfolk, Virginia, United States
Central Coast Neurosciences Research
🇦🇺Erina, New South Wales, Australia
St Vincent's Hospital Sydney; Neurology
🇦🇺Darlinghurst, New South Wales, Australia
UW Wisconsin-Madison
🇺🇸Madison, Wisconsin, United States
The Queen Elizabeth Hospital; Neurology
🇦🇺Woodville, South Australia, Australia
Southern Neurology
🇦🇺Kogarah, New South Wales, Australia
Heidelberg Repatriation Hospital; Medical and Cognitive Research Centre
🇦🇺Heidelberg West, Victoria, Australia
Neuro Trials Victoria
🇦🇺Noble Park, Victoria, Australia
Hospital Nossa Senhora das Graças; Setor de Pesquisa em Neurologia
🇧🇷Curitiba, PR, Brazil
Hospital das Clinicas - UFRGS
🇧🇷Porto Alegre, RS, Brazil
Hospital das Clinicas - FMUSP_X; Neurologia
🇧🇷Sao Paulo, SP, Brazil
Clínica Dr. Norton Sayeg LTDA - EPP
🇧🇷Sao Paulo, SP, Brazil
Clinica Clinilive ltda
🇧🇷Maringa, PR, Brazil
The Medical Arts Health Research Group - West Vancouver
🇨🇦Vancouver, British Columbia, Canada
Parkwood Hospital; Geriatric Medicine
🇨🇦London, Ontario, Canada
Centre for Memory and Aging
🇨🇦Toronto, Ontario, Canada
Center for Diagnosis and Research on Alzheimer's disease
🇨🇦Greenfield Park, Quebec, Canada
St. Michael'S Hospital
🇨🇦Toronto, Ontario, Canada
Devonshire Clinical Research
🇨🇦Woodstock, Ontario, Canada
Q & T Research Sherbrooke
🇨🇦Sherbrooke, Quebec, Canada
Alpha Recherche Clinique
🇨🇦Quebec, Canada
China-Japan Friendship Hospital
🇨🇳Beijing City, China
Beijing Anding Hospital, Capital Medical University
🇨🇳Beijing City, China
West China Hospital, Sichuan University
🇨🇳Chengdu, China
The First Affiliated Hospital, Chongqing Medical University
🇨🇳Chongqing, China
Fujian Medical University Union Hospital
🇨🇳Fuzhou City, China
Guangzhou First Municipal People's Hospital
🇨🇳Guangzhou, China
Sir Run Run Shaw Hospital
🇨🇳Hangzhou City, China
The Second Affiliated Hospital, Zhejiang University
🇨🇳Hangzhou, China
Anhui Provincial Hospital
🇨🇳Hefei, China
Zhongda Hospital Affiliated to Southeast University
🇨🇳Nanjing, China
Shanghai Mental Health Center
🇨🇳Shanghai, China
Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
🇨🇳Shanghai, China
The First Affiliated Hospital of Wenzhou Medical College
🇨🇳Wenzhou, China
The University of Hong Kong-Shenzhen Hospital; Local Ethic Committee
🇨🇳Shenzhen City, China
Hopital des Charpennes
🇫🇷Villeurbanne, France
Tianjin Medical University General Hospital
🇨🇳Tianjin, China
Henan Provincial People's Hospital
🇨🇳Zhengzhou, China
Hôpital Avicenne; Centre de Recherche Clinique
🇫🇷Bobigny Cedex, France
Groupement Hospitalier Est - Hôpital Neurologique; Neurologie A (U502)
🇫🇷Bron cedex, France
CHU Amiens Hopital Sud; Neurologie
🇫🇷Amiens Cedex1, France
CHU de la Timone - Hopital d Adultes; Service de Neurologie
🇫🇷Marseille, France
CHU Poitiers - Hopital La Miletrie
🇫🇷Poitiers, France
Hôpital Lariboisière
🇫🇷Paris, France
CHU Strasbourg Hôpital Hautepierre
🇫🇷Strasbourg, France
Gerontopole; Centre de Recherche clinique
🇫🇷Toulouse, France
Ambulates Gesundheitszentrum der Charité GmbH; MVZ Neurologie Campus Benjamin Franklin
🇩🇪Berlin, Germany
ECRC Experimental and Clinical Research Center, Charité Campus Berlin Buch, Memory Clinic
🇩🇪Berlin, Germany
St. Josef-Hospital, Klinik für Neurologie
🇩🇪Bochum, Germany
Universitätsklinikum Köln; Klinik und Poliklinik für Psychiatrie und Psychotherapie
🇩🇪Köln, Germany
Universitätsklinikum Münster; Klinik und Poliklinik für Neurologie
🇩🇪Münster, Germany
Universitätsklinikum Rostock Zentrum für Nervenheilkunde
🇩🇪Rostock, Germany
Klinikum rechts der Isar der TU München; Klinik für Psychiatrie und Psychotherapie
🇩🇪München, Germany
Forschungszentrum Ruhr
🇩🇪Witten, Germany
Studienzentrum Nordwest Dr med Joachim Springub Herr Wolfgang Schwarz
🇩🇪Westerstede, Germany
Jichiidai Station Brain Clinic
🇯🇵Tochigi, Japan
Semmelweis University; Department of Neurology
🇭🇺Budapest, Hungary
Umberto I Policlinico di Roma-Università di Roma La Sapienza
🇮🇹Roma, Lazio, Italy
Nuovo Ospedale Civile S. Agostino-Estense; Clinica Neurologica ? Dipartimento di Neuroscienze
🇮🇹Modena, Emilia-Romagna, Italy
IRCCS Ospedale San Raffaele; Centro Disturbi della Memoria
🇮🇹Milano, Lombardia, Italy
IRCCS ?Centro S. Giovanni di Dio? Fatebenefratelli -UO Alzheimer
🇮🇹Brescia, Lombardia, Italy
ASST DI MONZA; Neurologia
🇮🇹Monza, Lombardia, Italy
Dipartimento delle Patologie Emergenti; Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone
🇮🇹Palermo, Sicilia, Italy
Inage Neurology and Memory Clinic
🇯🇵Chiba, Japan
AO Città della Salute e della Scienza Osp.S.Giov.Battista Molinette; SC Geriatria
🇮🇹Torino, Piemonte, Italy
Shonan Kamakura General Hospital
🇯🇵Kanagawa, Japan
Hospital Nacional Cayetano Heredia; Servicio de Neurologia
🇵🇪San Martin de Porres, Peru
Juntendo University Urayasu Hospital
🇯🇵Chiba, Japan
Yuai Clinic
🇯🇵Kanagawa, Japan
Mishima Hospital
🇯🇵Niigata, Japan
NHO Shizuoka Institute of Epilepsy and Neurological Disorders
🇯🇵Shizuoka, Japan
Shizuoka City Shimizu Hospital
🇯🇵Shizuoka, Japan
Tokyo Medical and Dental University Hospital
🇯🇵Tokyo, Japan
Yotsuya Medical Cube
🇯🇵Tokyo, Japan
Tokyo Medical University Hospital
🇯🇵Tokyo, Japan
Tokyo Metropolitan Geriatric Hospital
🇯🇵Tokyo, Japan
Nozomi Memory Clinic
🇯🇵Tokyo, Japan
National Center of Neurology and Psychiatry
🇯🇵Tokyo, Japan
P-One Clinic
🇯🇵Tokyo, Japan
Yamagata Tokusyukai Hospital
🇯🇵Yamagata, Japan
Vilnius University Hospital Santariskiu Clinics; Neurology
🇱🇹Vilnius, Lithuania
Clinica Internacional; Unidad De Investigacion
🇵🇪Lima, Peru
Hospital Nacional Dos de Mayo; Unidad de Investigacion de Neurologia
🇵🇪Lima, Peru
University ?linic of headaches
🇷🇺Moscow, Moskovskaja Oblast, Russian Federation
FSBHI Siberian Clinical Center of the Federal Medical and Biological Agency
🇷🇺Krasnoyarsk, Krasnojarsk, Russian Federation
Russian Medical Military Academy n.a. S.M.Kirov; Neurology Department
🇷🇺St Petersburg, Sankt Petersburg, Russian Federation
City Clin Hosp n.a. S.P.Botkin
🇷🇺Moscow, Moskovskaja Oblast, Russian Federation
Vertebronevrologiya LLC
🇷🇺Kazan, Tatarstan, Russian Federation
City Clinical Hospital # 2 n.a. V.I. Razumovsky
🇷🇺Saratov, Russian Federation
Hospital Universitari de Bellvitge; Servicio de Neurologia
🇪🇸L'Hospitalet de Llobregat, Barcelona, Spain
Nebbiolo Center for Clinical Trials
🇷🇺Tomsk, Russian Federation
Hospital San Pedro; Servicio de Neurología
🇪🇸Logroño, LA Rioja, Spain
Hospital General De Catalunya; Servicio de Neurologia
🇪🇸Sant Cugat del Valles, Barcelona, Spain
Hospital Universitario Marques de Valdecilla; Servicio de Neurología
🇪🇸SANtander, Cantabria, Spain
Hospital General Universitario de Albacete; Servicio de Neurología
🇪🇸Albacete, Spain
HM Universitario Puerta del Sur CINAC (C.Integ.Neuroc);; Servicio de Psiquiatría
🇪🇸Móstoles, Madrid, Spain
Hospital de la Santa Creu i Sant Pau; Servicio de Neurologia
🇪🇸Barcelona, Spain
Hospital Clinic i Provincial; Servicio de Neurologia
🇪🇸Barcelona, Spain
Hospital Universitario Reina Sofia; Servicio de Neurologia
🇪🇸Cordoba, Spain
Hospital Ramon y Cajal; Servicio de Neurologia
🇪🇸Madrid, Spain
Hospital Virgen del Rocío; Servicio de Neurología
🇪🇸Sevilla, Spain
Hospital Universitario 12 de Octubre; Servicio de Neurologia
🇪🇸Madrid, Spain
Complejo Asistencial Universitario de Salamanca; Servicio de Psiquiatría
🇪🇸Salamanca, Spain
Hospital Universitario Dr. Peset; Servicio de Neurologia
🇪🇸Valencia, Spain
Servicio de Neurología Hospital Viamed Montecanal.
🇪🇸Zaragoza, Spain
Kaohsiung Medical University Hospital; Neurology
🇨🇳Kaohsiung, Taiwan
Chang Gung Memorial Foundation - Kaohsiung - Neurology
🇨🇳Niaosong Dist., Taiwan
National Taiwan University Hospital; Neurology
🇨🇳Taipei, Taiwan
Sutter Medical Group, Neurology
🇺🇸Sacramento, California, United States
Wasatch Clinical Research, LLC
🇺🇸Salt Lake City, Utah, United States
Medical Arts Health Research Group
🇨🇦Penticton, British Columbia, Canada
Hospital IV Alberto Sabogal Sologuren; Unidad de Investigacion
🇵🇪Bellavista, Peru
Changhua Christian Hospital; Neurology
🇨🇳Changhua County, Taiwan
Senior Adults Specialty Research
🇺🇸Austin, Texas, United States
Neurological Associates, Inc.
🇺🇸Richmond, Virginia, United States
National Clinical Research Inc.-Richmond
🇺🇸Richmond, Virginia, United States
Related News
Amyloid-Related Imaging Abnormalities in Clinical Trials of Gantenerumab in Early ...
- Prev
- 1
- Next